Investigation of the effects of intranasal botulinum toxin type A and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia
- PMID: 18444492
Investigation of the effects of intranasal botulinum toxin type A and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia
Abstract
Idiopathic rhinitis without eosinophilia is a group of frequently observed diseases, the aetiopathogenesis of which is not yet well known. One of the most disturbing symptoms for patients within this disease group is nasal hypersecretion. Although many different treatments have been tried for hypersecretion, nasal topical drugs form the basis of any such therapy today. Ipratropium bromide (IB) is a drug offirst choice in nasal hypersecretion therapy. It displays a parasympatholytic effect in topical use and antagonizes acetylcholine transport in efferent parasympathetic nerves, thus decreasing submucosal gland secretion, which is the cause of hypersecretion. Botulinum toxin type A (BTX-A) is among the alternative treatment choices that is increasingly used in symptomatic treatment of nasal hypersecretion. Our study was planned with the aim of comparing the effect of these two groups of drugs on nasal hypersecretion. Thirty-eight patients who were diagnosed with idiopathic rhinitis without eosinophilia were included in the study and were divided in 3 different groups: In the first group, a total of 10 units of BTX-A were injected into both nasal cavities. In the second group, 3x2 IB was injected into both nasal cavities for 4 weeks. The third group received intranasal physiologic saline as placebo. The patients were evaluated in terms of nasal hypersecretion with visual analogue scale prior to the treatment and at weeks 1, 2, 4, 8, and 12 during the follow-up period. Throughout the 8 weeks follow-up period, the patient complaints displayed a 41.2% decrease in the group that received BTX-A and a 61.4% decrease in the group which received IB, while no change was observed in the control group. Both drug groups were well tolerated by the patients, with no serious adverse or systemic effects. As a result, while IB and BTX-A differ in terms of method of application, they display a similar degree and duration of efficiency in hypersecretion therapy.
Similar articles
-
Double-blind study of intranasal ipratropium bromide in nonallergic perennial rhinitis.Ann Allergy. 1992 Jul;69(1):53-60. Ann Allergy. 1992. PMID: 1385682 Clinical Trial.
-
The effect of intranasal injection of botulinum toxin A on the symptoms of vasomotor rhinitis.Am J Otolaryngol. 2006 Sep-Oct;27(5):314-8. doi: 10.1016/j.amjoto.2006.01.008. Am J Otolaryngol. 2006. PMID: 16935174 Clinical Trial.
-
Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: a double-blind, placebo-controlled clinical trial.Acta Otolaryngol. 2003 Dec;123(9):1060-3. doi: 10.1080/00016480310000755. Acta Otolaryngol. 2003. PMID: 14710908 Clinical Trial.
-
Effects of intranasal xylometazoline, alone or in combination with ipratropium, in patients with common cold.Curr Med Res Opin. 2010 Apr;26(4):889-99. doi: 10.1185/03007991003648015. Curr Med Res Opin. 2010. PMID: 20151787 Review.
-
Intranasal ipratropium: literature abstracts and comments.Rhinol Suppl. 1989;9:37-44. Rhinol Suppl. 1989. PMID: 2534054 Review.
Cited by
-
[Research progress of botulinum toxin type A in the treatment of chronic rhinitis].Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Nov;36(11):878-883. doi: 10.13201/j.issn.2096-7993.2022.11.015. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022. PMID: 36347585 Free PMC article. Review. Chinese.
-
An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions.JRSM Short Rep. 2013 Feb;4(2):10. doi: 10.1177/2042533312472115. Epub 2013 Feb 12. JRSM Short Rep. 2013. PMID: 23476731 Free PMC article.
-
Septal injection in comparison with inferior turbinates injection of botulinum toxin A in patients with allergic rhinitis.J Res Med Sci. 2013 May;18(5):400-4. J Res Med Sci. 2013. PMID: 24174945 Free PMC article.
-
Temporomandibular Myofacial Pain Treated with Botulinum Toxin Injection.Toxins (Basel). 2015 Jul 24;7(8):2791-800. doi: 10.3390/toxins7082791. Toxins (Basel). 2015. PMID: 26213970 Free PMC article. Review.
-
Botulinum Toxin for Rhinitis.Curr Allergy Asthma Rep. 2016 Aug;16(8):58. doi: 10.1007/s11882-016-0636-3. Curr Allergy Asthma Rep. 2016. PMID: 27461136 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials